Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review

Ferreira, Luana Mota; Cerezer, Jaderson Lima; Gehrcke, Mailine

doi:10.1016/j.htct.2020.05.009

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytomegalovirus activation is also an important complication of this therapy. [17] Hemophagocytic syndrome has also been reported with its use. Like Rituximab this can also be given by subcutaneous route without losing its efficacy.…”

Section: Description and Uses Of Monoclonal Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Monoclonal antibodies used for management of hematological disorders

Ghosh

2021

JHAS

View full text Add to dashboard Cite

Objectives: Monoclonal antibodies (MAs) are increasingly becoming part of therapeutic armamentarium for hematologists and hemato-oncologists. There is paucity of review on majority of these antibodies in one place. The objective of this review is an attempt to fill the gap in paucity of review on majority of these monoclonal antibodies (MAs) in one place. Material and Methods: ‘Pubmed’ and ‘Scopus’ database was explored focusing on monoclonal antibodies (MAs) in clinical hematological practice. Emphasis was given to the more recently published review articles on different monoclonal antibodies (MAs). Results: In the present review, a total of 23 different monoclonal antibodies (MAs) were discussed; some are very frequently used and some rarely. Monoclonal antibodies (MAs) are used for treatment of diverse hematological conditions, i.e. malignant and benign disorders and at various phases of stem cell transplantation. These antibodies were used either alone or in combination with various chemotherapeutic agents, targeted small molecules or as immunoconjugates. Some of the side effect profiles of these antibodies were common and some were unique to the particular monoclonal antibody (MA). Unusual infections or organ dysfunctions were noted. Improved function of antibodies by protein engineering is also advancing rapidly. Dosage, frequency and route of administration depended on the convenience and condition for which the antibody is used. Conclusion: Monoclonal antibodies (MAs) are going to stay for hematological practice. Some amount of familiarity with their usage, advantages, disadvantages and side effects are essential in clinical practice.

show abstract

Section: Description and Uses Of Monoclonal Antibodiesmentioning

confidence: 99%

“…The safety and side effects of monoclonal antibodies (MAs) has been reviewed elsewhere. [12,17,78] Antibody immunoconjugates produce additional and peculiar side effects. [70] Some of the antibodies have ophthalmic, cardiac, hepatic and hematological side effects.…”

Section: Side Effectsmentioning

confidence: 99%